PL EN


2014 | 1 | 44-47
Article title

Czynniki dobrej odpowiedzi na leczenie przeciwwirusowe zakażenia HBV

Content
Title variants
EN
Factors that predict response to hepatitis B treatment
Languages of publication
PL
Abstracts
PL
Duża liczba osób zakażonych wirusem zapalenia wątroby typu B na świecie i w Polsce oraz ograniczona dostępność i skuteczność leczenia przyczynowego wymusza poznanie czynników odpowiedzi na stosowaną terapię. Ma to na celu wybranie jak najlepszego leku oraz możliwość modyfikacji leczenia w trakcie terapii. W pracy omówiono poznane czynniki/znaczniki odpowiedzi na leczenie zakażenia HBV. Czynnikami dobrej odpowiedzi na terapię PEG-IFN wyjściowo są: niska wiremia HBV DNA , obecność HBeAg, wysoka aktywność Al at, genotyp A lub B HBV oraz wysoka aktywność zapalna w badaniu histopatologicznym bioptatu wątroby. Monitorowanie skuteczności leczenia przeciwwirusowego oceną wiremii HBV DNA metodą PCR , ilościowego oznaczania HBsAg, HBeAg i kinetyki spadku tych stężeń umożliwia modyfikację leczenia w trakcie jego trwania. Dalej istnieje potrzeba selekcjonowania nowych czynników pozwalających przewidywać skuteczność prowadzonego leczenia przeciwwirusowego u zakażonych HBV w celu ograniczenia ryzyka rozwoju odległych powikłań, tj. rozwoju marskości wątroby ze wszystkimi następstwami, oraz raka wątrobowokomórkowego
A large number of people infected with hepatitis B virus in Poland and the world as well as limited availability and efficiency of causal therapy necessitate further research on predictors of response to the therapy. It has to provide choosing the best medication and capability to modify the therapy. The paper discusses predictors of responses to the HBV therapy. Factors associated with response to PEG-IFN therapy are: low HBV DNA level, HBeAg presence, high Al at activity and active inflammation in histopathological examination of the liver biopsy. Modification of the therapy is possible by monitoring its effectiveness by using the assessment of HBV DNA levels with PCR method, HBsAg quantification and kinetics of the decrease in their concentrations. There is still a need to discover new factors that will let predict the efficiency of the antiviral therapy in HBV positive patients to decrease the risk of developing the long-term complications such as liver cirrhosis and hepatocellular cancer
Contributors
References
  • EAS L Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.
  • Simon K, red. Diagnostyka chorób wątroby. Poznań: Termedia; 2012: 7–309.
  • Simon K, Piszko P. Zakażenie HBV – obraz kliniczny, współczesne zasady diagnostyki i możliwości leczenia. Fam Med Prim Care Rev 2010; 12(2): 9–14.
  • Wang Y-X, Zheng S-M, Zhang Y, et al. Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patients with poor virological response to peginterferon alfa. Scand J Gastroenterol 2013; 48: 213–217.
  • Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067–1077.
  • Marcellin P, Gane E, Buti M. Regression of cirrhosis during tenofovir disoproxil fumarate treatment for chronic hepatitis B.Lancet 2012; Doi:10.1016/S0140-6736(12)61425-1.
  • Liaw YF , Gane E, Leung N. GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136(2): 486–495.
  • Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699–705.
  • Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alpha. Gastroenterology 2009; 137: 2002–2009.
  • Chow WC , Manns M, Paik SW , et al. Effect of ethnicity, genotype, gender, age and bodyweight on sustained response in
  • a large, randomised study of peginterferon alfa-2A +/- lamivudine versus lamivudine alone for HBeAg-positive chronic hepatitis B. Hepatology 2005; 42(Suppl. 1): 576A.
  • Zeuzem S, Buti M, Gane EJ, et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE study). Hepatology 2007; 46(Suppl. 5): 681A.
  • Cindoruk, Mehmet MD, Karakan, et al. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol 2007; 41: 513–517.
  • Keeffe EB, Zeuzem S, Koff RS , et al. Report of an international workshop: roadmap for management of patients receiving oral herapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890–897.
  • Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009–1013.
  • Erhard A, Ludwig AD, Brunetto M, et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients [Abstract]. Hepatology 2008; 48(Suppl 1): 700A.
  • Chow WC , Cooksley G, Chang WY , et al. Predicting response in a large multinational trail of peginterferon alfa-2a +/- lamivudine vs lamivudine alone for HbeAg-positive chronic hepatitis B. Liver Int 2005; 25: AB138.
  • Chu CJ, Lok AS . Clinical significance of hepatitis B virus genotypes. Hepatology 2002; 35: 1274–1276.
  • Sonneveld MJ, Rijckborst V, Boucher CA , et al. Prediction and sustained response to peginterferon alfa-2b for hepatitis B eantigen-positive chronic B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251–1257.
  • Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAgnegative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454–461.
  • Jaroszewicz J. Praktyczne zastosowani ilościowego oznaczania stęż eń antygenu HBs. Med Sci Rev – Hepatologia 2011; 11:33–36.
  • Wursthorn K, Jung M, Riva A. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52(5): 1611–1620
  • Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis B surface antigen kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2012; 3: 676–683.
  • Fried MW , Piratvisuth T, Lau GK. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47(2): 428–434.
  • Perrillo RP, Lai CL, Liaw YF , et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186–194.
  • Rosmawati M, Lai CL, Lao J, et al. Baseline ALT level does not predict viral load reduction in response to entecavir therapy.J Hepatol 2003; 38(Suppl. 2): 166A–167A.
  • Vermehren J, Kau A, Zeuzem S. Baseline and on-treatment predictors for outcome of chronic hepatitis B treatment. Curr Hepatitis Rep 2010; 9: 53–59.
  • Lampertico P, Vigano M, Cheroni Ch, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B. Hepatology 2013; 57(3): 890–896
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.desklight-311b3897-ae80-42d4-95c2-134cf501bcf6
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.